Skip to main content

Table 2 Evolution of RA patients’ disease activity during the 24-months follow-up

From: Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study

 

Day 0

W6

M3

M6

M9

M12

M18

M24

P1

DAS 28

1.76

3.14

2.43

2.43

1.76

1.55

5.18

1.64

RTI

4

6

6

6

6

8

8

6

Dose

4

4

4

4

4

4

4

4

P2

DAS 28

1.69

2.35

2.79

2.89

2.69

3.14

1.34

2.13

RTI

4

6

6

8

6

8

4

4

Dose

8

8

8

8

8

8

8

8

P3

DAS 28

2.4

2.07

2.57

3.92

2.14

3.7

3.68

2.61

RTI

4

6

6

8

4

4

5

4

Dose

8

8

8

8

8

8

8

8

P4

DAS 28

2.6

1.42

1.34

1.94

1.05

1.12

3.35

1.49

RTI

4

6

8

8

4

5

5

5

Dose

8

8

8

8

8

8

8

8

P5

DAS 28

2.58

2.6

1.61

2.11

2.23

2.22

2.03

0.91

RTI

4

6

6

7

8

8

9

9

Dose

8

8

8

8

8

8

8

8

P6

DAS 28

0.48

NA

0.76

1.37

0.28

0.28

2.22

1.84

RTI

4

6

7

6

6

6

8

9

Dose

8

8

8

8

8

8

8

8

P 7

DAS 28

1.61

NA

2.57

1.34

1.94

3.28

2

2.5

RTI

4

5

8

8

8

8

8

8

Dose

6

8

8

6

6

6

8

8

P8

DAS 28

1.98

2.26

1.68

2.14

NA

1.81

2.42

Secondary failure Switch to infliximab

RTI

4

6

6

8

8

8

4

Dose

8

8

8

8

8

8

4

P9

DAS 28

0.07

1.45

1.89

1.89

1.12

0.76

0.76

1.12

RTI

4

6

6

7

7

8

9

10

Dose

8

8

8

8

8

8

8

8

P10

DAS 28

1.38

3.2

NA

2.85

2.45

3.71

Secondary failure Switch to abatacept

RTI

4

6

4

4

4

4

Dose

8

8

8

8

8

8

P11

DAS 28

2.31

2.31

3.48

0.85

Neutropenia

Switch to abatacept

RTI

4

5

6

4

Dose

4

4

6

6

P12

DAS 28

2.56

1.03

4.08

3.51

Secondary failure

Switch to abatacept

RTI

4

6

6

4

Dose

8

8

8

8

P13

DAS 28

0

1.03

1.55

2.57

5.35

Secondary failure

Switch to abatacept

RTI

4

6

6

8

6

Dose

6

6

6

6

6

  1. Dose mg/kg, W week, M month, P patient, RTI retreatment interval, NA not available
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us